Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Google IncTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Inovio Pharmaceuticals Inc — how do they compare? Google Inc trades at $370.49 (market cap $4.52T), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Google Inc is far larger — about 46956.2× Inovio Pharmaceuticals Inc's market cap, and Google Inc pays a 0.24% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

GOOGINO
Market Cap
$4.52T$96.26M
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$2.87
52-Week Low
$183.77$1.05
Enterprise Value
$4.49T$67.27M
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

Inovio Pharmaceuticals Inc

INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.

The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO